Ticker Hub
SLXN — AI Analysis & Sentiment
3 recent AI-generated analyses for SLXN. Sentiment and confidence insights updated continuously.
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics' $1 million capital raise is insufficient to offset its high cash burn and introduces substantial future dilution risk from n...
May 15, 2026Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has achieved a significant milestone with regulatory approval to begin Phase 2/3 trials for its lead pancreatic cancer candid...
Mar 24, 2026Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Silexion Therapeutics has advanced its lead drug SIL204 towards Phase 2/3 clinical trials, a critical milestone for a clinical-stage oncology compa...
Mar 17, 2026